← Eichor
Study identifier: NCT06797999 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma

Condition: Metastatic Soft Tissue Sarcoma · Unresectable Soft Tissue Sarcoma  ·  Sponsor: Adcendo ApS

PhasePhase 1/Phase 2
Planned participants270
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.

This description comes directly from the study's public registry record.

Talk to the study team

René Smrčka  ·  +45 3144 0653  ·  rene.smrcka@adcendo.com

Margaret McNaull  ·  +44 7818 457619.  ·  margaret.mcnaull@adcendo.com

Always discuss trial participation with your own doctor first.

Locations (8)

University of Colorado DenverAurora, Colorado, United StatesRecruiting
University of Miami - Sylvester Comprehensive Cancer CenterMiami, Florida, United StatesRecruiting
Memorial Sloan Kettering Cancer CenterNew York, New York, United StatesRecruiting
University Of Texas MD Anderson Cancer CenterHouston, Texas, United StatesRecruiting
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus GasthuisbergLeuven, BelgiumRecruiting
Centre Léon BérardLyon, FranceRecruiting
Universitätsklinikum Essen West German Tumor CenterEssen, GermanyRecruiting
Royal MarsdenLondon, United KingdomNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06797999